Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases

Zeng, Liuting; Yang, Kailin; Wu, Yang; Yu, Ganpeng; Yan, Yexing; Hao, Moujia; Song, Tian; Li, Yuwei; Chen, Junpeng; Sun, Lingyun

doi:10.1016/j.jaut.2024.103291

Journal of Autoimmunity

2024

DOI: 10.1016/j.jaut.2024.103291

|View full text |Cite

Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases

Liuting Zeng,

Kailin Yang,

Yang Wu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report

Ling,

Zhang,

Guo

et al. 2024

Lupus

View full text Add to dashboard Cite

Background Lupus cystitis, a severe complication of systemic lupus erythematosus (SLE), presents considerable treatment challenges. Purpose This case report describes the use of telitacicept in treating severe SLE with lupus cystitis. Research Design A single patient with lupus cystitis. Study Sample A patient with symptoms including frequent urination, urgency, and acute urinary retention. Data Collection and Analysis Initial treatments included corticosteroid pulse therapy, immunoglobulin, and cyclophosphamide, which improved laboratory indicators but failed to alleviate symptoms of urinary retention. The patient was then treated with telitacicept. Results Significant alleviation of urinary retention was observed shortly after incorporating telitacicept into the treatment regimen. The patient's condition remained stable with no relapse during the subsequent 10 months of follow-up. Conclusions This case highlights the therapeutic potential of telitacicept for SLE patients who are unresponsive to conventional therapies, particularly those with severe manifestations such as lupus cystitis.

show abstract

Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report

Ling,

Zhang,

Guo

et al. 2024

Lupus

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases

Cited by 1 publication

References 147 publications

Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report

Telitacicept for refractory cystitis associated with severe systemic lupus erythematosus: A case report

Contact Info

Product

Resources

About